Pu Yuan-Zhu, Su Can
School of Chinese Materia Medica, Yunnan University of Chinese Medicine Kunming 650500, China.
Yunnan Provincial Academy of Science and Technology Kunming 650051, China.
Zhongguo Zhong Yao Za Zhi. 2020 Dec;45(23):5650-5657. doi: 10.19540/j.cnki.cjcmm.20200717.602.
Alzheimer's disease(AD) is a neurodegenerative disease that has no effective drug to cure it. Studies in several AD models have shown that Erigeron breviscapus and its active ingredients(scutellarin and caffeoylquinic acid) could improve/enhance the learning and memory ability, and the mechanisms are associated with inhibiting amyloid β(Aβ) production, aggregation, fibrosis and Aβ neurotoxicity toxicity, regulating cholinergic nervous system, inhibiting oxidative stress and inflammation, inhibiting tau hyperphosphorylation, improving mitochondrial function, and resisting neuronal apoptosis. This article systematically reviewed the research progress of E. breviscapus and its active ingredients for treatment of AD in AD models, in the expectation of providing references for further development of E. breviscapus's medicinal potential.
阿尔茨海默病（AD）是一种没有有效治愈药物的神经退行性疾病。在多个AD模型中的研究表明，灯盏花及其活性成分（灯盏乙素和咖啡酰奎宁酸）可以改善/增强学习和记忆能力，其机制与抑制淀粉样β蛋白（Aβ）的产生、聚集、纤维化及Aβ神经毒性、调节胆碱能神经系统、抑制氧化应激和炎症、抑制tau蛋白过度磷酸化、改善线粒体功能以及抵抗神经元凋亡有关。本文系统综述了灯盏花及其活性成分在AD模型中治疗AD的研究进展，以期为进一步开发灯盏花的药用潜力提供参考。
